Conversion to rapamycin in a renal transplant patient with von Hippel-Lindau disease: encouraging results-a case report.
von Hippel-Lindau (VHL) disease is a genetic syndrome based on an abnormality of the VHL gene located on the short arm of chromosome 3. Clinically, it presents as multiple tumors at several levels. The VHL gene product (pVHL) acts as a tumor-suppressing protein. In conditions of hypoxia it leads to an increase in several growth factor levels. mTOR inhibitors have proved to have dual properties: immunosuppressive and antitumor effects. Herein we have presented a case in which conversion to sirolimus improved graft function and also caused regression of retinal angioblastomas.
Henriquez
F
F
Nephrology Service, Hospital Universitario de Gran Canaria "Dr. Negrin," Gran Canaria, Spain. fer_henriquez@hotmail.com
Gallego
R
R
Oliva
E
E
Silva
D
D
Vega
N
N
D000230:Adenocarcinoma / Q000601:surgery; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000601:surgery; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis; D020123:Sirolimus / Q000627:therapeutic use*; D016896:Treatment Outcome; D006623:von Hippel-Lindau Disease / Q000601:surgery*
D007166:Immunosuppressive Agents; D020123:Sirolimus